The HIV prevention drug cabotegravir, which is delivery by injection every eight weeks, is not yet available in Canada.
The next step in HIV prevention — long-acting injectable pre-exposure prophylaxis (PrEP) — is not yet available in Canada, a year after its approval in the U.S.
Remembering to take a pill every day can be a barrier to good adherence.
Daniel Born/The Times/Gallo Images/Getty Images
The benefit of an injectable product is that it avoids the adherence issues related to taking a pill daily.
Some countries, like Kenya, Uganda, South Africa, Zambia, and Nigeria, have been more proactive than others, but it is still hard for many to get PrEP.
The omission of growing evidence that Māori, and Māori women in particular, have worse health outcomes after HIV infection could derail New Zealand’s elimination plans and exacerbate disparities.
PrEP can reduce the risk of HIV infection by over 90%.
Daniel Born/The Times/Gallo Images/GettyImages
PrEP enables adolescent girls and young women to protect themselves from HIV without having to convince a partner to use a condom at the time of sex.
Difficult to understand communication and the somewhat overstated benefits of male circumcision may lead to increased risky sexual behaviour.
Facebook recently disabled some ads on its site making dubious claims about Truvada.
AP Photo/Rich Pedroncelli
Facebook began blocking ads that linked Truvada and other HIV-related drugs to severe bone and kidney damage based on claims made in lawsuits.
Australians are safer too if temporary visitors can access HIV prevention.
Eradicating a virus from the community requires everyone to have access to prevention, as is the case with tuberculosis. So why not HIV?
There needs to be a wide range of sexual health services for men who have sex with men.
In many parts of sub-Saharan Africa men who have sex with men encounter stigma and prejudice when accessing health services.
South Africa’s data rollout of its pre-exposure prophylaxis shows that there is a relatively slow, but increasing, uptake. However, more needs to be done to target young women.
Three new HIV vaccine concepts which rely on high-tech designer proteins are being trialled to see if they can stop the virus.
There are several challenges that South Africa needs to address to bring HIV under control.
South Africa has made tremendous progress towards meeting the 90-90-90 targets but there are some challenges preventing it from reaching the goals set by UNAIDS.
Antiretroviral drugs suppress the HIV virus and stop progression of the disease.
The introduction of Pre Exposure Prophylaxis drugs in Kenya aims at reducing new HIV infections among people facing substantial ongoing risk.
A study of 78 Kenyan secondary schools shows up critical gaps in sex education.
At a time when a new national school curriculum is starting its pilot phase in Kenya, a study shows the massive gaps in sexuality education programmes.
Medical circumcision in settings where there are high rates of HIV will only be successful if these interventions take into account local beliefs about circumcision.
Philanthropist Bill Gates addresses delegates at the 2016 Aids Conference in Durban.
Bill Gates, who has been identified as the world’s most significant donor in the fight against AIDS, shares his thoughts on the pandemic with Africa’s most prominent HIV/AIDS academics.
There is a link between online social networking technologies and increased risky sexual behaviour.
Online social networking technologies have been linked with increased risky sexual behaviour – and Swaziland is no different.
Pre-exposure prophylaxis is providing an exciting new innovation to tackle HIV prevention.
Trials have shown that rates of HIV infection are reduced if people not infected with HIV take anti-retrovirals - known as pre-exposure prophylaxis (PrEP). But adherence to a daily dose is a problem.
Doing it differently.
Ignoring those at ‘high risk’ of HIV in order to sustain the idea of the ‘good’ gay man will only perpetuate the virus.
For the next five years South Africa will be leading one of the latest large-scale trials for a vaccine for HIV.